Skip to content
Study details
Enrolling now

EUS-RFA PANCARDINAL-1 Trial

The University of Texas Health Science Center, Houston
NCT IDNCT04990609ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

60

Study length

about 6.8 years

Ages

18+

Locations

1 site in TX

What this study is about

This trial is testing whether endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) plus standard chemotherapy can be used to treat pancreatic ductal adenocarcinoma (PDAC). The treatment will be given before surgery, with the goal of shrinking or stopping cancer spread so that surgery might be less invasive and more effective.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Neoadjuvant Chemotherapy (NAC)
  • 2.Use Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: Disease-free survival time, Radiographic treatment response as assessed by standard Response evaluation criteria in solid tumors (RECIST) criteria